Observationsstudie af VYKAT™ XR hos patienter med Prader-Willi-syndrom
Et observationsstudie af VYKAT™ XR (Diazoxidcholin-tabletter med kontrolleret frigivelse) hos patienter med Prader-Willi-syndrom (PWS)
Prospective observational study developed to generate more evidence of the safety profile, clinical characteristics and outcomes of patients with PWS treated with VYKAT XR.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Patients with PWS at participating sites who are initiating treatment or have initiated treatment with VYKAT XR, including patients who were previously treated with DCCR in a prior clinical study, will be invited to participate. Data from treatment prior to enrollment either from clinical practice or from previous DCCR clinical trials may be collected retrospectively.
Clinical care will not be mandated by the protocol.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85016
- Soleno Clinical Site
-
-
California
-
Los Angeles, California, Forenede Stater, 90027
- Soleno Clinical Site
-
Sacramento, California, Forenede Stater, 95821
- Soleno Clinical Site
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Soleno Clinical Site
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32608
- Soleno Clinical Site
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Soleno Clinical Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Soleno Clinical Site
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Soleno Clinical Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Soleno Clinical Site
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Soleno Clinical Site
-
Lansing, Michigan, Forenede Stater, 48912
- Soleno Clinical Site
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55454
- Soleno Clinical Site
-
Rochester, Minnesota, Forenede Stater, 55905
- Soleno Clinical Site
-
Saint Paul, Minnesota, Forenede Stater, 55102
- Soleno Clinical Site
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64111
- Soleno Clinical Site
-
-
New Jersey
-
Paterson, New Jersey, Forenede Stater, 07503
- Soleno Clinical Site
-
-
New York
-
Valley Stream, New York, Forenede Stater, 11580
- Soleno Clinical Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Soleno Clinical Site
-
Durham, North Carolina, Forenede Stater, 27710
- Soleno Clinical Site
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97227
- Soleno Clinical Site
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Soleno Clinical Site
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75231
- Soleno Clinical Site
-
Houston, Texas, Forenede Stater, 77030
- Soleno Clinical Site
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84108
- Soleno Clinical Site
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Soleno Clinical Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
This study will enroll patients with PWS who are currently receiving or initiating treatment with VYKAT XR.
Beskrivelse
Inclusion Criteria:
- Patients currently receiving or initiating treatment with VYKAT XR, including patients who previously received DCCR or are transitioning from DCCR to VYKAT XR in the context of a prior DCCR clinical trial.
- Patients and/or caregivers must provide written informed consent.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Patients with PWS who are currently receiving or initiating treatment with VYKAT XR.
All patients with PWS at participating sites who are initiating treatment or have initiated treatment with VYKAT XR at the time of enrollment into this observational study, including patients who were previously treated with DCCR in a prior clinical study, will be invited to participate. Although the overall observational study is prospective, data from treatment prior to enrollment into the observational study, either from clinical practice or from DCCR clinical trials, may be collected retrospectively. |
All prospective treatment in this protocol will be commercial VYKAT XR prescribed to patients by their physicians in addition to their standard of care; patients will not receive experimental intervention or treatment from the Sponsor as part of their participation in this study.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Assess safety profile of patients with PWS treated with VYKAT XR.
Tidsramme: Adverse events for each patient will be collected from the time of first dose on VYKAT XR until the last contact with the patient.
|
The safety profile will be based on adverse events, including nonserious adverse events, serious adverse events, and adverse events leading to discontinuation of VYKAT XR. |
Adverse events for each patient will be collected from the time of first dose on VYKAT XR until the last contact with the patient.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Prægningsforstyrrelser
- Neurologiske manifestationer
- Sygdomme i nervesystemet
- Ernæringsforstyrrelser
- Genetiske sygdomme, medfødte
- Overernæring
- Neuroadfærdsmæssige manifestationer
- Medfødte abnormiteter
- Abnormiteter, multiple
- Overvægtig
- Intellektuel handicap
- Fedme
- Kromosomlidelser
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Prader-Willi syndrom
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- C623
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .